Gilead says remdesivir shows improvement in COVID-19 patients when used early


Gilead Sciences Inc’s experimental antiviral drug remdesivir helped improve symptoms in COVID-19 patients who were given the drug early than among those who were treated later, the company said. 

The closely-watched drug has moved markets in the past few weeks and on Wednesday broader markets once again rose on the data and Gilead shares also jumped 9%.

In Gilead’s study, 62% of patients treated early were discharged from the hospital, compared with 49% of patients who were treated late, the company said in a press release. 

The trial was testing 397 patients, evaluating the safety and efficacy of five-day and 10-day dosing regimens of remdesivir in hospitalized patients with severe manifestations of COVID-19.

Read the full article here.